When was Adaptive Biotechnologies founded?

Adaptive Biotechnologies was founded in 2009 and raised its 1st funding round within a year of its incorporation.

Where is Adaptive Biotechnologies located?

Adaptive Biotechnologies is headquartered in Seattle, United States. It is registered at 1551 EASTLAKE AVE E STE 200 SEATTLE, WA 98102.

How many employees does Adaptive Biotechnologies have?

As of Jul 31, 2026, the latest employee count at Adaptive Biotechnologies is 651.

Is Adaptive Biotechnologies a funded company?

Adaptive Biotechnologies is a funded company, having raised a total of $419M across 18 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 28, 2009.

When was the latest funding round of Adaptive Biotechnologies?

Adaptive Biotechnologies' latest funding was a $***** Series F round on Jan 22, 2018, with participation from 1 investor. Its primary sector is Infectious Diseases. In United States, the Infectious Diseases sector has seen $880M in funding in 2026 to date.

What is the annual revenue of Adaptive Biotechnologies?

Annual revenue of Adaptive Biotechnologies is between $100M and $500M as on Dec 31, 2025

Where does Adaptive Biotechnologies rank among its competitors?

Adaptive Biotechnologies ranks 1st amongst 369 active competitors, of which 83 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Daye, which secured $576K in Nov, 2025.

Who are the top competitors of Adaptive Biotechnologies?

Adaptive Biotechnologies' top competitors include MeMed, HaystackAnalytics and Huwel Life. Among them, Daye secured the most recent funding round in November, 2025.

Adaptive Biotechnologies - 2026 Company Profile, Funding, Competitors & Financials

Adaptive Biotechnologies is a public company based in Seattle (United States), founded in 2009. It operates as a Provider of clinical diagnostics, and drug discovery for immune diseases. Adaptive Biotechnologies has raised $419M in funding from Viking Global Investors and Matrix. The company has 369 active competitors, including 83 funded and 53 that have exited. Its top competitors include companies like MeMed, HaystackAnalytics and Huwel Life.

Company Details

Provider of clinical diagnostics, and drug discovery for immune diseases. The company's immune profiling sequencing technology immunoSEQ enables the characterization of the immune system, helping scientists & clinicians in research and drug development. The company also offers clonoSEQ for monitoring Minimal Residual Disease (MRD) in blood-based cancers. Also, develops cell therapies, vaccines, and antibody molecules for infectious diseases.

Website: www.adaptivebiotech.com/
Social
Email ID: *****@adaptivebiotech.com, *****@adaptivebiotech.com
Phone Number: +1 **********
Registered Address: 1551 EASTLAKE AVE E STE 200 SEATTLE, WA 98102

Key Metrics

Founded Year

2009

Location

Seattle, United States

Stage

Public

Total Funding

$419M in 18 rounds

Latest Funding Round

Series F, Jan 22, 2018, $*****

Investors

Viking Global Investors & 22 more

Ranked

1^st among 369 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

651 as on Jul 31, 2026

Investment & Acquisitions

Sequenta

Similar Companies

MeMed & 428 more

Exit Details

Public

View Adaptive Biotechnologies' full profile

Adaptive Biotechnologies is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Adaptive Biotechnologies Corp CIN: 1478320 , United States, Active	Nov 03, 2019	$100M - $500M (As on Dec 31, 2025)	-	-
ADAPTIVE BIOTECHNOLOGIES CORPORATION CIN: 270907024 , Belgium, Active	Sep 07, 2009	-	609 (As on Dec 31, 2022)	-

Adaptive Biotechnologies got listed on Jun 27, 2019.

Click here to take a look at Adaptive Biotechnologies's IPO in detail

Adaptive Biotechnologies has raised a total funding of $419M over 18 rounds. Its first funding round was on Dec 28, 2009. Its latest funding round was a Series F round on Jan 22, 2018 for $*****. 1 investor participated in its latest round. Adaptive Biotechnologies has 23 institutional investors.

Here is the list of recent funding rounds of Adaptive Biotechnologies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 22, 2018	9805371	Series F	2056763	9605875	2513449	5915247
May 06, 2015	3585272	Series F	6191563	6389643	6954240	Rock Springs Capital & 9 more
Jan 21, 2015	2915880	Series E	4873008	4728341	2675626	9757608

Access funding benchmarks and valuations. Sign up today!

View details of Adaptive Biotechnologies's funding rounds and investors

Adaptive Biotechnologies' employee count trend

Adaptive Biotechnologies has 651 employees as of Jul 26. Here is Adaptive Biotechnologies's employee count trend over the years:

Employee count trend for Adaptive Biotechnologies

Uncover Adaptive Biotechnologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Adaptive Biotechnologies include MeMed, HaystackAnalytics and Huwel Life. Here is the list of Top 10 competitors of Adaptive Biotechnologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	HTIF, Foresite Capital & 21 others	72/100
2nd	MeMed 2009, Tirat Carmel (Israel), Series D	Provider of machine learning based diagnostic solutions for infectious diseases	$163M	La Maison Partners, Ping An & 23 others	69/100
3rd	HaystackAnalytics 2018, Mumbai (India), Seed	Provider of genomics technology for personalized clinical decisions	$17.3M	STRIVE, Sun Pharma & 33 others	67/100
4th	Huwel Life 2015, Hyderabad (India), Series A	Molecular diagnostic solutions and products for the healthcare industry	$5.74M	Bartronics, BIRAC & 3 others	59/100
5th	Karius 2014, Redwood City (United States), Series C	Provider of diagnostics for identifying infectious diseases using microbial DNA	$315M	Khosla Ventures, Gilde Healthcare & 16 others	58/100
6th	Mylab 2016, Pune (India), Seed	Developer of diagnostic kits for pathogen detection and viral load monitoring	-	Rising Sun Holdings, Zydus Life & 10 others	57/100
7th	Seegene Technologies 2000, Seoul (South Korea), Public	Provider of advanced molecular diagnostics solutions	-	IMM Investment, Songhyun Investment & 3 others	56/100
8th	Daye 2018, London (United Kingdom), Series A	Manufacturer of period care products and provider of health tests	$19.2M	Index Ventures, Salica Investments & 24 others	56/100
9th	Clear Labs 2014, Menlo Park (United States), Series D	Provider of food safety technologies for the identification of pathogens	$171M	Menlo Ventures, Redmile Group & 26 others	56/100
10th	Quantamatrix 2010, Seoul (South Korea), Public	Multiplexed platform for disease daignosis	$198K	Treatment Action Group, Shield Investment ... & 6 others	55/100